DMAA
NASDAQ
$10.70
Drugs Made In America Acquisition Corp (DMAA)
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company dedicated to revolutionizing the U.S. pharmaceutical sector through strategic partnerships with innovative healthcare firms. Focused on bolstering domestic drug production and mitigating supply chain risks, DMAA aims to enhance the accessibility and affordability of medications for American consumers. By harnessing advanced technologies and championing local manufacturing efforts, DMAA is poised to significantly influence the landscape of pharmaceutical access in the United States.
This company is also listed under the following tickers: DMAAR, DMAAU.
Website: https://dmaacorp.comSector:
Financial Services
Industry:
Shell Companies
Market Cap
$246M
P/E Ratio
41.84
Free Cash Flow Yield
-0.10%
Beta (5Y)
0.01
Price Chart
Valuation
Market Cap$246M
P/E41.84
P/B1.10
Profitability
EBITDA-$539K
EPS$0.26
Financial Health
Debt-to-Equity0%
Free Cash Flow Yield-0.10%
Growth & Risk
Beta (5Y)0.01
Sharpe Ratio0.34